{"id":956580,"date":"2026-04-30T08:28:05","date_gmt":"2026-04-30T12:28:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/"},"modified":"2026-04-30T08:28:05","modified_gmt":"2026-04-30T12:28:05","slug":"diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/","title":{"rendered":"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwpadl0 { padding-left: 0px }\n.bwpadr0 { padding-right: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignb { vertical-align: bottom }\n.bwwidth100 { width: 100% }\n.bwwidth20 { width: 20% }\n.bwwidth80 { width: 80% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026<\/b><\/p>\n<p>MINNEAPOLIS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6<sup>th<\/sup>. DiaMedica will host a live conference call on Thursday, May 7<sup>th<\/sup> at 8:00 AM Eastern Time \/ 7:00 AM Central Time to provide a business update and discuss financial results.<\/p>\n<p>\nConference Call details:<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0 bwwidth20\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\nDate:<\/p>\n<\/td>\n<td class=\"bwpadl0 bwwidth80\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\nThursday, May 7, 2026<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth20\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\nTime:<\/p>\n<\/td>\n<td class=\"bwpadl0 bwwidth80\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n8:00 AM EDT \/ 7:00 AM CDT<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth20\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\nWeb access:<\/p>\n<\/td>\n<td class=\"bwpadl0 bwwidth80\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fus-west-2.protection.sophos.com%3Fd%3Dwebinar.net%26u%3DaHR0cHM6Ly9hcHAud2ViaW5hci5uZXQvbkczeVB6UlA3d2s%3D%26i%3DNjU1NmE0NWY4MzA0ZjA2ZTMwNTBjNWRl%26t%3Ddm9sVFRPa3JpSGY2MDdnVUpkVmIxNFFCekRhU1BPL0RrNWhiWnQrTERLOD0%3D%26h%3D0cd202ecbf514a9d93523d8d72e9f0aa%26s%3DAVNPUEhUT0NFTkNSWVBUSVb0jT9XNCpnwtiDPzDkWPaiLuiD7NL75STTkolMAGSvWg&amp;esheet=54523615&amp;newsitemid=20260430443041&amp;lan=en-US&amp;anchor=https%3A%2F%2Fapp.webinar.net%2FnG3yPzRP7wk&amp;index=1&amp;md5=e54907a8d53a8c7704d06da315b8c5bf\">https:\/\/app.webinar.net\/nG3yPzRP7wk<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth20\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\nDial In:<\/p>\n<\/td>\n<td class=\"bwpadl0 bwwidth80\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n(646) 357-8766<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth20\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\nConference ID:<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwalignl bwwidth80\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6195397<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nInterested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on the Company\u2019s website, under <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.diamedica.com%2Finvestors%2Fevents-presentations&amp;esheet=54523615&amp;newsitemid=20260430443041&amp;lan=en-US&amp;anchor=investor+relations+-+events+and+presentations&amp;index=2&amp;md5=576f0f0e5355acf67f14cf31e67c2c10\">investor relations &#8211; events and presentations<\/a>, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 14, 2026, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 6195397#.<\/p>\n<p><b><i>About DiaMedica Therapeutics Inc.<\/i><\/b><\/p>\n<p>\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica\u2019s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.diamedica.com&amp;esheet=54523615&amp;newsitemid=20260430443041&amp;lan=en-US&amp;anchor=www.diamedica.com&amp;index=3&amp;md5=8e0ce8823c9e6f36c87829c82416335d\">www.diamedica.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260430443041\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260430443041\/en\/<\/a><\/span><\/p>\n<p>\nScott Kellen<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/>Phone: (763) 496-5118<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:skellen@diamedica.com\">skellen@diamedica.com<\/a><\/p>\n<p><b>For Investor Inquiries:<br \/>\n<\/b><br \/>Mike Moyer<br \/>\n<br \/>Managing Director, LifeSci Advisors, LLC<br \/>\n<br \/>Phone: (617) 308-4306<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mmoyer@lifesciadvisors.com\">mmoyer@lifesciadvisors.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Madelin Hawtin<br \/>\n<br \/>LifeSci Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mhawtin@lifescicomms.com\">mhawtin@lifescicomms.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Minnesota United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> FDA Baby\/Maternity Clinical Trials Cardiology Biotechnology Health Consumer Pharmaceutical General Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260430443041\/en\/2786096\/3\/DiaMedica-Logo-white-background.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6th. DiaMedica will host a live conference call on Thursday, May 7th at 8:00 AM Eastern Time \/ 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, May 7, 2026 Time: 8:00 AM EDT \/ 7:00 AM CDT Web access: https:\/\/app.webinar.net\/nG3yPzRP7wk Dial In: (646) 357-8766 Conference ID: 6195397 Interested &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-956580","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6th. DiaMedica will host a live conference call on Thursday, May 7th at 8:00 AM Eastern Time \/ 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, May 7, 2026 Time: 8:00 AM EDT \/ 7:00 AM CDT Web access: https:\/\/app.webinar.net\/nG3yPzRP7wk Dial In: (646) 357-8766 Conference ID: 6195397 Interested &hellip; Continue reading &quot;DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T12:28:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026\",\"datePublished\":\"2026-04-30T12:28:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/\"},\"wordCount\":362,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/\",\"name\":\"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-04-30T12:28:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/","og_locale":"en_US","og_type":"article","og_title":"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - Market Newsdesk","og_description":"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6th. DiaMedica will host a live conference call on Thursday, May 7th at 8:00 AM Eastern Time \/ 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, May 7, 2026 Time: 8:00 AM EDT \/ 7:00 AM CDT Web access: https:\/\/app.webinar.net\/nG3yPzRP7wk Dial In: (646) 357-8766 Conference ID: 6195397 Interested &hellip; Continue reading \"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-30T12:28:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026","datePublished":"2026-04-30T12:28:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/"},"wordCount":362,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/","name":"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-04-30T12:28:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260430443041r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-business-update-may-7-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=956580"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956580\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=956580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=956580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=956580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}